Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly

Autoimmunity Reviews

Volumn 11, Issue 2, 2011, Pages 149-153

  Sardi, F ^a   Fassina, L ^a   Venturini, L ^a,b   Inguscio, M ^a,b   Guerriero, F ^a,b   Rolfo, E ^a,b   Ricevuti, G ^a,b  

^a UNIVERSITY OF PAVIA   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Alzheimer; Antibodies; Autoimmunity; Complement; Inflammation; Memory

Indexed keywords

APOLIPOPROTEIN E; COMPLEMENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN; ALPHA 1 ANTICHYMOTRYPSIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE (NADPH); IL10 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGING; ALZHEIMER DISEASE; AUTOIMMUNITY; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; DISEASE COURSE; GENETIC POLYMORPHISM; HUMAN; IMMUNE STATUS; INFLAMMATION; MEMORY; PATHOGENESIS; REVIEW; T LYMPHOCYTE; AGED; AMYLOID PLAQUE; BRAIN; DRUG EFFECT; GENETICS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; METABOLISM; NERVE CELL; PATHOLOGY;

AGED; ALPHA 1-ANTICHYMOTRYPSIN; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOLIPOPROTEINS E; AUTOIMMUNITY; BLOOD-BRAIN BARRIER; BRAIN; COMPLEMENT SYSTEM PROTEINS; HUMANS; HYDROXYMETHYLGLUTARYL-COA-REDUCTASES, NADP-DEPENDENT; IMMUNOLOGIC MEMORY; INFLAMMATION; INTERLEUKIN-10; INTERLEUKIN-1BETA; NEURONS; PLAQUE, AMYLOID; POLYMORPHISM, GENETIC; T-LYMPHOCYTES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861325911     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2011.09.005     Document Type: Review

References (70)

1. D'Andrea M.R. Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res 2003, 982:19-30.
2. Strous R.D., Shoenfeld Y. To smell the immune system: olfaction, autoimmunity and brain involvement. Autoimmun Rev 2006, 6:54-60.
3. Evseev V.A., Davydova T.V., Mikovskaya O.I. Dysregulation in neuroimmunopathology and perspectives of immunotherapy. Bull Exp Biol Med 2001, 131:305-308.
4. Combarros O., Infante J., Rodriguez E., Llorca J., Pena N., Fernandez-Viadero C., et al. CD14 receptor polymorphism and Alzheimer's disease risk. Neurosci Lett 2005, 380:193-196.
5. Arshavsky Y.I. Alzheimer's disease, brain immune privilege and memory: a hypothesis. J Neural Transm 2006, 113:1697-1707.
6. Chorsky R.L., Yaghmai F., Hill W.D., Stopa E.G. Alzheimer's disease: a review concerning immune response and microischemia. Med Hypotheses 2001, 56:124-127.
7. Schram M.T., Euser S.M., de Craen A.J., Witteman J.C., Frolich M., Hofman A., et al. Systemic markers of inflammation and cognitive decline in old age. J Am Geriatr Soc 2007, 55:708-716.
8. Mackay I.R., Leskovsek N.V., Rose N.R. The odd couple: a fresh look at autoimmunity and immunodeficiency. J Autoimmun 2010, 35:199-205.
9. Vasto S., Malavolta M., Pawelec G. Age and immunity. Immun Ageing 2006, 3:2.
10. McGeer P.L., McGeer E.G. The possible role of complement activation in Alzheimer disease. Trends Mol Med 2002, 8:519-523.
11. Rosenau B.J., Schur P.H. Antibody to serum amyloid A. J Autoimmun 2004, 23:179-182.
12. Witkowski J.M., Bryl E. Paradoxical age-related cell cycle quickening of human CD4(+) lymphocytes: a role for cyclin D1 and calpain. Exp Gerontol 2004, 39:577-585.
13. Davies A.J. Immunological tolerance and the autoimmune response. Autoimmun Rev 2008, 7:538-543.
14. Franceschi C., Bonafè M., Valensin S., Olivieri F., De Luca M., Ottaviani E., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci 2000, 908:244-254.
15. Boren E., Gershwin M.E. Inflamm-aging: autoimmunity, and the immune-risk phenotype. Autoimmun Rev 2004, 3:401-406.
16. Giunta S. Is inflammaging an auto[innate]immunity subclinical syndrome?. Immun Ageing 2006, 3:12.
17. Gershwin M.E. The mosaic of autoimmunity. Autoimmun Rev 2008, 7:161-163.
18. Stojanovich L., Marisavljevich D. Stress as a trigger of autoimmune disease. Autoimmun Rev 2008, 7:209-213.
19. Mantovani A., Garlanda C., Locati M., Rodriguez T.V., Feo S.G., Savino B., et al. Regulatory pathways in inflammation. Autoimmun Rev 2007, 7:8-11.
20. Town T. Inflammation, immunity, and Alzheimer's disease. CNS Neurol Disord Drug Targets 2010, 9:129-131.
21. Zandman-Goddard G., Shoenfeld Y. Hyperferritinemia in autoimmunity. Isr Med Assoc J 2008, 10:83-84.
22. Gupta A., Pansari K. Inflammation and Alzheimer's disease. Int J Clin Pract 2003, 57:36-39.
23. van Beek J., Elward K., Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann N Y Acad Sci 2003, 992:56-71.
24. Scrivo R., Vasile M., Bartosiewicz I., Valesini G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev 2011, 10:369-374.
25. Zotova E., Nicoll J.A., Kalaria R., Holmes C., Boche D. Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther 2010, 2:1.
26. Taguchi H., Planque S., Nishiyama Y., Szabo P., Weksler M.E., Friedland R.P., et al. Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease. Autoimmun Rev 2008, 7:391-397.
27. McGeer E.G., McGeer P.L. Innate immunity in Alzheimer's disease: a model for local inflammatory reactions. Mol Interv 2001, 1:22-29.
28. Blasko I., Stampfer-Kountchev M., Robatscher P., Veerhuis R., Eikelenboom P., Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004, 3:169-176.
29. Grathwohl S.A., Kalin R.E., Bolmont T., Prokop S., Winkelmann G., Kaeser S.A., et al. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci 2009, 12:1361-1363.
30. Weller R.O., Preston S.D., Subash M., Carare R.O. Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther 2009, 1:6.
31. Ringheim G.E., Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004, 147:43-49.
32. Bach J.F. Infections and autoimmune diseases. J Autoimmun 2005, 25(Suppl):74-80.
33. Mrak R.E., Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 2001, 22:903-908.
34. Campisi G., Chiappelli M., De Martinis M., Franco V., Ginaldi L., Guiglia R., et al. Pathophysiology of age-related diseases. Immun Ageing 2009, 6:12.
35. Sciacca F.L., Ferri C., Licastro F., Veglia F., Biunno I., Gavazzi A., et al. Interleukin-1B polymorphism is associated with age at onset of Alzheimer's disease. Neurobiol Aging 2003, 24:927-931.
36. Arosio B., Trabattoni D., Galimberti L., Bucciarelli P., Fasano F., Calabresi C., et al. Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease. Neurobiol Aging 2004, 25:1009-1015.
37. Lio D., Licastro F., Scola L., Chiappelli M., Grimaldi L.M., Crivello A., et al. Interleukin-10 promoter polymorphism in sporadic Alzheimer's disease. Genes Immun 2003, 4:234-238.
38. Licastro F., Candore G., Lio D., Porcellini E., Colonna-Romano G., Franceschi C., et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005, 2:8.
39. Weisgraber K.H., Rall S.C., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J Biol Chem 1981, 256:9077-9083.
40. Licastro F., Porcellini E., Caruso C., Lio D., Corder E.H. Genetic risk profiles for Alzheimer's disease: integration of APOE genotype and variants that up-regulate inflammation. Neurobiol Aging 2007, 28:1637-1643.
41. Del Bo R., Scarlato M., Ghezzi S., Martinelli B.F., Fenoglio C., Galbiati S., et al. Vascular endothelial growth factor gene variability is associated with increased risk for AD. Ann Neurol 2005, 57:373-380.
42. Querfurth H.W., LaFerla F.M. Alzheimer's disease. N Engl J Med 2010, 362:329-344.
43. Mattila K.M., Pirttila T., Blennow K., Wallin A., Viitanen M., Frey H. Altered blood-brain-barrier function in Alzheimer's disease?. Acta Neurol Scand 1994, 89:192-198.
44. Vugler A., Lawrence J., Walsh J., Carr A., Gias C., Semo M., et al. Embryonic stem cells and retinal repair. Mech Dev 2007, 124:807-829.
45. D'Andrea M.R. Add Alzheimer's disease to the list of autoimmune diseases. Med Hypotheses 2005, 64:458-463.
46. Emmerling M.R., Watson M.D., Raby C.A., Spiegel K. The role of complement in Alzheimer's disease pathology. Biochim Biophys Acta 2000, 1502:158-171.
47. McGeer P.L., McGeer E.G. Innate immunity, local inflammation, and degenerative disease. Sci Aging Knowledge Environ 2002, 2002(re3):1-9.
48. Lal H., Forster M.J. Autoimmunity and age-associated cognitive decline. Neurobiol Aging 1988, 9:733-742.
49. Steinman L. State of the art. Four easy pieces: interconnections between tissue injury, intermediary metabolism, autoimmunity, and chronic degeneration. Proc Am Thorac Soc 2006, 3:484-486.
50. Hawkes C.A., McLaurin J. Immunotherapy as treatment for Alzheimer's disease. Expert Rev Neurother 2007, 7:1535-1548.
51. Singh V.K., Fudenberg H.H. Increase of immunoglobulin G3 subclass is related to brain autoantibody in Alzheimer's disease but not in Down's syndrome. Autoimmunity 1989, 3:95-101.
52. Singh V.K., Yang Y.Y., Singh E.A. Immunoblot detection of antibodies to myelin basic protein in Alzheimer's disease patients. Neurosci Lett 1992, 147:25-28.
53. Singh V.K. Immune-activation model in Alzheimer disease. Mol Chem Neuropathol 1996, 28:105-111.
54. Landreth G.E., Reed-Geaghan E.G. Toll-like receptors in Alzheimer's disease. Curr Top Microbiol Immunol 2009, 336:137-153.
55. Patel N.S., Paris D., Mathura V., Quadros A.N., Crawford F.C., Mullan M.J. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005, 2:9.
56. Hanisch U.K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007, 10:1387-1394.
57. Styren S.D., Civin W.H., Rogers J. Molecular, cellular, and pathologic characterization of HLA-DR immunoreactivity in normal elderly and Alzheimer's disease brain. Exp Neurol 1990, 110:93-104.
58. Fassbender K., Walter S., Kuhl S., Landmann R., Ishii K., Bertsch T., et al. The LPS receptor (CD14) links innate immunity with Alzheimer's disease. FASEB J 2004, 18:203-205.
59. Kielian T. Toll-like receptors in central nervous system glial inflammation and homeostasis. J Neurosci Res 2006, 83:711-730.
60. Walter S., Letiembre M., Liu Y., Heine H., Penke B., Hao W., et al. Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol Biochem 2007, 20:947-956.
61. Udan M.L., Ajit D., Crouse N.R., Nichols M.R. Toll-like receptors 2 and 4 mediate Abeta(1-42) activation of the innate immune response in a human monocytic cell line. J Neurochem 2008, 104:524-533.
62. Gruden M.A., Davidova T.B., Malisauskas M., Sewell R.D., Voskresenskaya N.I., Wilhelm K., et al. Differential neuroimmune markers to the onset of Alzheimer's disease neurodegeneration and dementia: autoantibodies to Abeta((25-35)) oligomers, S100b and neurotransmitters. J Neuroimmunol 2007, 186:181-192.
63. Colasanti T., Barbati C., Rosano G., Malorni W., Ortona E. Autoantibodies in patients with Alzheimer's disease: pathogenetic role and potential use as biomarkers of disease progression. Autoimmun Rev 2010, 9:807-811.
64. Geylis V., Steinitz M. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies. Autoimmun Rev 2006, 5:33-39.
65. Lutz H.U., Miescher S. Natural antibodies in health and disease: an overview of the first international workshop on natural antibodies in health and disease. Autoimmun Rev 2008, 7:405-409.
66. McIntyre J.A., Chapman J., Shavit E., Hamilton R.L., Dekosky S.T. Redox-reactive autoantibodies in Alzheimer's patients' cerebrospinal fluids: preliminary studies. Autoimmunity 2007, 40:390-396.
67. Moir R.D., Tseitlin K.A., Soscia S., Hyman B.T., Irizarry M.C., Tanzi R.E. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 2005, 280:17458-17463.
68. Szabo P., Relkin N., Weksler M.E. Natural human antibodies to amyloid beta peptide. Autoimmun Rev 2008, 7:415-420.
69. Neff F., Wei X., Nolker C., Bacher M., Du Y., Dodel R. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders. Autoimmun Rev 2008, 7:501-507.
70. Dodel R., Neff F., Noelker C., Pul R., Du Y., Bacher M., et al. Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs 2010, 70:513-528.